Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Reviva reported a Q3 2026 net loss of approximately $2.3 million, or $0.17 per share, down from $4.0 million, or $1.09 per share, a year earlier, with cash of $17.5 million at quarter end. The company expects FDA feedback in Q4 2026 on use of a new brilaroxazine formulation in the RECOVER-2 Phase 3 trial and a future schizophrenia NDA, followed by a Q1 2027 bioequivalence study and 1H 2027 RECOVER-2 enrollment start. Enrollment is explicitly subject to additional financing, and the company plans to apply for Nasdaq relisting in 1H 2027 after being relegated to OTCQB following a 1:20 reverse split.
Key figures
- Revenue
- 0
- Net loss q3 2025
- 4000000
- Net loss q3 2026
- 2300000
- Rd expense q3 2026
- 1198460
- Reverse split ratio
- 1:20 (effected March 9, 2026)
- Cash and equivalents
- 17500000
- Patent protection through
- 2046
- Operating expenses q3 2026
- 2432518
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.